報價延遲最少15分鐘:2024/05/16 22:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
171.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.54/-0.65
|
|
企業價值
17.46B
|
| 資產負債 |
|
每股賬面淨值
32.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.46B
|
|
每股收益
17.32
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 22:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, theUnited States, and the Rest of the world. |